GENF Stock Overview
Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Genflow Biosciences plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.016 |
| 52 Week High | UK£0.044 |
| 52 Week Low | UK£0.013 |
| Beta | 2.47 |
| 1 Month Change | 10.17% |
| 3 Month Change | -2.99% |
| 1 Year Change | -61.31% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| GENF | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 3.2% | -0.4% | 2.2% |
| 1Y | -61.3% | -29.1% | 0.9% |
Return vs Industry: GENF underperformed the UK Biotechs industry which returned -29.5% over the past year.
Return vs Market: GENF underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| GENF volatility | |
|---|---|
| GENF Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: GENF's share price has been volatile over the past 3 months.
Volatility Over Time: GENF's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 5 | Eric Leire | genflowbio.com |
Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use.
Genflow Biosciences plc Fundamentals Summary
| GENF fundamental statistics | |
|---|---|
| Market cap | UK£5.68m |
| Earnings (TTM) | -UK£1.18m |
| Revenue (TTM) | UK£194.07k |
29.3x
P/S Ratio-4.8x
P/E RatioIs GENF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENF income statement (TTM) | |
|---|---|
| Revenue | UK£194.07k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£194.07k |
| Other Expenses | UK£1.38m |
| Earnings | -UK£1.18m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0034 |
| Gross Margin | 100.00% |
| Net Profit Margin | -609.62% |
| Debt/Equity Ratio | 0% |
How did GENF perform over the long term?
See historical performance and comparison